The high protein expression levels observed in NSCLC across all histologies (8), particularly among those with advanced disease (9), provided the initial impetus for the early lung cancer trials targeting the EGFR pathway by small molecule tyrosine kinase inhibitors (EGFR-TKIs) and anti-EGFR monoclonal antibodies. This evidence concerns the gene EGFR and lung cancer.